Skip to main content
SpringerLink
Log in

Tumeurs de vessie

  • Chapter
Pelvi-périnéologie

  • 643 Accesses

Résumé

Deux grands groupes de tumeurs de vessie doivent être individualisés: les tumeurs superficielles respectant le muscle vésical (elles représentent 70 à 80 % des cas) et les tumeurs infiltrantes qui envahissent ou dépassent le muscle vésical. Dans le traitement des lésions superficielles envahissant le chorion, la résection endoscopique est souvent incomplète malgré l’impression macroscopique de l’urologue: six semaines après le geste, des reliquats tumoraux sont observés dans plus de 40 % des cas. La résection endoscopique est insuffisante à traiter une tumeur infiltrante: la cystectomie totale est le traitement de référence de ces lésions. L’immunothérapie endovésicale (bacille de Calmette et Guérin (BCG)) a une place importante dans le traitement des tumeurs superficielles de vessie à haut risque de progression, à la fois dans la prévention des récidives et dans la prévention ou le retard à la progression tumorale. La chimiothérapie trouve son indication dans les tumeurs localement avancées ou métastatiques. L’association radiothérapie plus chimiothérapie est l’alternative thérapeutique conservatrice qui obtient les meilleurs résultats dans les tumeurs infiltrantes de vessie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Jemal A, Murray T, Samuels A et al. (2003) Cancer Statistics, 2003. CA Cancer J Clin 53: 5–26

    PubMed  Google Scholar 

  2. Chopin D, Gattegno B (2001) Épidémiologie descriptive des tumeurs de la vessie. Prog Urol 11: 955–60

    CAS  PubMed  Google Scholar 

  3. Chopin D, Vordos D, Gattegno B (2001) Étiologies des tumeurs superficielles de vessie. Prog Urol 11: 927–52

    CAS  PubMed  Google Scholar 

  4. Sobin LH, Wittekind C (2003) TNM. Classification of malignant tumors. Sixth Edition. UICC International Union Against Cancer, Ed Willey-Liss: 193–5

    Google Scholar 

  5. Epstein JI, Amin MB, Reuter VR et al. (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435–48

    CAS  PubMed  Google Scholar 

  6. Lutzeyer W, Rubben H, Dahm H (1982) Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 127: 250–2

    CAS  PubMed  Google Scholar 

  7. Heney NM, Ahmed S, Flanagan MJ et al. (1983) Superficial bladder cancer: progression and recurrence. J Urol 130: 1083–6

    CAS  PubMed  Google Scholar 

  8. Herr HW (1997) Natural history of superficial bladder tumors: 10-to 20-year follow-up of treated patients. World J Urol 15: 84–8

    Article  CAS  PubMed  Google Scholar 

  9. Herr HW, Jakse G, Sheinfeld J (1990) The T1 bladder tumor. Semin Urol 8: 254–61

    CAS  PubMed  Google Scholar 

  10. Lamm DL (1992) Carcinoma in situ. Urol Clin North Am 19: 499–508

    CAS  PubMed  Google Scholar 

  11. Riddle PR, Chisholm GD, Trott PA et al. (1975) Flat carcinoma in Situ of bladder. Br J Urol 47: 829–33

    CAS  PubMed  Google Scholar 

  12. Herr HW, Schwalb DM, Zhang ZF et al. (1995) Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 13: 1404–8

    CAS  PubMed  Google Scholar 

  13. Gattegno B, Chopin D (2001) Histoire naturelle des tumeurs superficielles de vessie. Prog Urol 11: 963–90

    CAS  PubMed  Google Scholar 

  14. Zerbib M, Bouchot O (2002) Résultats de la cystectomie pour cancer. Prog Urol 12: 913–22

    PubMed  Google Scholar 

  15. Renaudin K, Moreau A, Buzelin F (2002) Histopronostic des tumeurs urothéliales infiltrantes. Prog Urol 12: 803–4

    PubMed  Google Scholar 

  16. Herr HW (1998) Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 16: 1099–102

    CAS  PubMed  Google Scholar 

  17. Schips L, Augustin H, Zigeuner RE et al. (2002) Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 59: 220–3

    PubMed  Google Scholar 

  18. Vincendeau S, De Lajarte-Thirouard AS, Bensalah K et al. (2003) Différenciation neuroendocrine des tumeurs de vessie. Prog Urol 13: 375–84

    PubMed  Google Scholar 

  19. Renaudin K, Moreau A et al. (2002) Anatomie pathologique des tumeurs épithéliales infiltrantes de vessie. Prog Urol 12: 787–802

    PubMed  Google Scholar 

  20. Kurth K, Denis L, Sylvester R et al. (1992) The natural history and the prognosis of treated superficial bladder cancer. EORTC GU Group. Prog Clin Biol Res 378: 1–7

    CAS  PubMed  Google Scholar 

  21. Klan R, Loy V, Huland H (1991) Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 146: 316–8

    CAS  PubMed  Google Scholar 

  22. Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162: 74–6

    CAS  PubMed  Google Scholar 

  23. Patard JJ, Rodriguez A, Lobel B (2003) The current status of intravesical therapy for superficial bladder cancer. Curr Opin Urol 13: 357–62

    PubMed  Google Scholar 

  24. Kaasinen E, Rintala E, Hellstrom P et al. (2002) Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42: 167–74.

    Article  PubMed  Google Scholar 

  25. Lamm DL, Griffith JG (1992) Intravesical therapy: does it affect the natural history of superficial bladder cancer? Semin Urol 10: 39–44

    CAS  PubMed  Google Scholar 

  26. Huncharek M, McGarry R, Kupelnick B (2001) Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 21: 765–9

    CAS  PubMed  Google Scholar 

  27. Nomata K, Noguchi M, Kanetake H et al. (2002) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment. Cancer Chemother Pharmacol 50: 266–70

    Article  CAS  PubMed  Google Scholar 

  28. Oosterlinck W, Kurth KH, Schroder F et al. (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149: 749–52

    CAS  PubMed  Google Scholar 

  29. Tolley DA, Parmar MK, Grigor KM et al. (1996) The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol 155: 1233–8

    CAS  PubMed  Google Scholar 

  30. Patard JJ, Saint F, Velotti F et al. (1998) Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res 26: 155–9

    Article  CAS  PubMed  Google Scholar 

  31. Lamm DL, Thor DE, Harris SC et al. (1980) Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124: 38–40

    CAS  PubMed  Google Scholar 

  32. Lamm DL, Blumenstein BA, Crawford ED et al. (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205–9

    CAS  PubMed  Google Scholar 

  33. Lamm DL, Blumenstein BA, Crissman JD et al. (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124–9

    CAS  PubMed  Google Scholar 

  34. Martinez-Pineiro JA, Flores N, Isorna S et al. (2002) Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 89: 671–80

    CAS  PubMed  Google Scholar 

  35. Lamm DL, Thor DE, Stogdill VD et al. (1982) Bladder cancer immunotherapy. J Urol 128: 931–5

    CAS  PubMed  Google Scholar 

  36. De Kernion JB, Huang MY, Lindner A et al. (1985) The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin. J Urol 133: 598–601

    Google Scholar 

  37. Sylvester RJ, Van der MA, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964–70

    Article  CAS  PubMed  Google Scholar 

  38. Patard JJ, Rodriguez A, Leray E et al. (2002) Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 41: 635–41; discussion 642

    Article  PubMed  Google Scholar 

  39. Malmstrom PU (2002) A randomized comparative dose-ranging study of interferon-alpha and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BJU Int 89: 681–6

    Article  CAS  PubMed  Google Scholar 

  40. Mohanty NK, Malhotra V, Nayak RL et al. (2002) Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up. J Chemother 14: 194–7

    CAS  PubMed  Google Scholar 

  41. Joudi FN, Smith BJ, O’Donnell MA et al. (2003) Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology 62: 1083–8

    Article  PubMed  Google Scholar 

  42. Mansson A, Davidsson T, Hunt S et al. (2002) The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference? BJU Int 90: 386–90

    Article  CAS  PubMed  Google Scholar 

  43. Vallancien G, Abou El Fettouh H, Cathelineau X et al. (2002) Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 168: 2413–7

    Article  PubMed  Google Scholar 

  44. Amling CL, Thrasher JB, Frazier HA et al. (1994) Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151: 31–5; discussion 35-6

    CAS  PubMed  Google Scholar 

  45. Zerbib M, Thirouard D, Conquy S et al. (1998) (Advances in surgical techniques and results of radical cystectomies for bladder cancer. 106 patients). Cancer Radiother 2: 505–11

    CAS  PubMed  Google Scholar 

  46. Lebret T, Herve JM, Yonneau L et al. (2000) Study of survival after cystectomy for bladder cancer. Report of 504 cases. Prog Urol 10: 553–60

    CAS  PubMed  Google Scholar 

  47. Sternberg CN, de Mulder PH, Schornagel JH et al. (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19: 2638–46

    CAS  PubMed  Google Scholar 

  48. Sternberg CN, Yagoda A, Scher HI et al. (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64: 2448–58

    CAS  PubMed  Google Scholar 

  49. Bamias A, Aravantinos G, Deliveliotis C et al. (2004) Docetaxel and Cisplatin With Granulocyte Colony-Stimulating Factor (G-CSF) Versus MVAC With GCSF in Advanced Urothelial Carcinoma: A Multicenter, Randomized, Phase III Study From the Hellenic Cooperative Oncology Group. J Clin Oncol 22: 220–8

    Article  CAS  PubMed  Google Scholar 

  50. Stockle M, Meyenburg W, Wellek S et al. (1992) Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148: 302–6; discussion 306-7

    CAS  PubMed  Google Scholar 

  51. Fossa SD, Waehre H, Aass N et al. (1993) Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients. Cancer 72: 3036–43

    CAS  PubMed  Google Scholar 

  52. Chauvet B, Brewer Y, Felix-Faure C et al. (1996) Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy. J Urol 156: 1258–62

    Article  CAS  PubMed  Google Scholar 

  53. Birkenhake S, Martus P, Kuhn R et al. (1998) Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer. Strahlenther Onkol 174: 121–7

    CAS  PubMed  Google Scholar 

  54. Herr HW, Scher HI (1994) Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 12: 975–80

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’urologie, CHRU Pontchaillou, 2, rue Henri-Le-Guillou, 35033, Rennes

    J.-J. Patard, K. Bensalah & F. Guillé

Authors
  1. J.-J. Patard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Bensalah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Guillé
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag France

About this chapter

Cite this chapter

Patard, JJ., Bensalah, K., Guillé, F. (2005). Tumeurs de vessie. In: Pelvi-périnéologie. Springer, Paris. https://doi.org/10.1007/2-287-27807-9_42

Download citation

  • DOI: https://doi.org/10.1007/2-287-27807-9_42

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-00501-5

  • Online ISBN: 978-2-287-27807-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation